All In Biotech

Drug Trial Radar · NCT03770936

Effect of Some Drugs on Liver Fibrosis

Clinical Study Evaluating the Efficacy of Renin Angiotensin System Inhibitors on the Extent of Liver Fibrosis in Patients With Chronic Hepatitis C

Last checked: Nov 20, 2026Latest source record: Dec 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Oct 1, 2018

Primary completion

Oct 2026

Study completion Nov 2027

Sponsor

Lead sponsor
Sherief Abd-ElsalamAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 10, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Effect of Some Drugs on Liver Fibrosis

Conditions

  • Liver Fibroses

Interventions

  • CandesartanDrug

    Candesartan 8 mg/day

  • RamiprilDrug

    ramipril 1.25 mg/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Fibroscan or APRI scoreTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sherief Abd-Elsalam

    Tanta, Egypt · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.